

13th International Conference on

BIOLOGICS AND BIOSIMILARS & BIOPHARMA & BIOTHERAPEUTICS

October 24-25, 2018 | Boston, USA

Robert Swift

Invenux LLC Windsor, US

Process development with Chinese Hamster Ovary and hybridoma cell lines: Differences, challenges, things to know

When utilizing different cell lines, expression, productivity and upstream process design, in general, need to be adapted to the metabolism and behavior of these cells. In the upstream process, critical to achieving high biosimilar yields are the choice of the expression system and cell line. For biosimilars, this a rapidly changing landscape as biosimilar manufacturers are no longer bound by technologies used decades ago to produce the original biologic. This Workshop will discuss these choices for Chinese Hamster Ovary (CHO) and Hybridoma cell lines.

Biography

Robert Swift is trained as a molecular biologist and virologist. He is the managing member of Invenux, LLC, a clinical stage pharmaceutical company.

robert@invenux.com

Notes: